

BÖLÜM 20

Santral Uyku Apne Sendromu



Veysi TEKİN¹

GİRİŞ

Uykuda solunum bozukluğu; horlama, obstrüktif uyku apnesi (OSA), santral uyku apnesi (CSA), solunumla ilgili uyarılmalar ve hipoventilasyon dahil olmak üzere bir dizi patolojik durumu içerir.

Santral uyku apne sendromu; solunum çabasının olmadığı, üst solunum yolu obstrüksiyonu olmaksızın tekrarlayan apne epizodları, desatürasyon, arousal'lar ve gündüz bulguları ile karakterizedir. Bazı tipleri alveoler hipoventilasyonla birliktedir ve hiperkapni oluşur, bazılarında da normokapni veya hipokapni oluşur (1).

Sonuç olarak santral apneler önemli komorbiditelere ve kardiyovasküler hastalık riskinde ciddi artışa sebep olabilir(2).

Yetişkinlerde santral uyku apnesinin en sık görülen iki nedeni, konjestif kalp yetmezliği ve opioidlerin kronik olarak kullanılmasıdır(3). Santral uyku apnesinin tanı ve tedavisinin bilinmesi bu hastalığa bağlı morbidite ve mortaliteyi ciddi şekilde azaltabilir.

SUAS ICSD-3 (International Classification of Sleep Disorders-3) tanımlamasına göre 8 alt gruba ayrılmıştır.

1. CHEYNE-STOKES SOLUNUMLA BİRLİKTE OLAN SUAS

Central sleep apnea-cheyne stokes respiration (CSA-CSR); santral apne ve hipopnelerin, tipik olarak artan ve azalan bir solunum modeli olarak tanınan hipoventilasyon periyotları ile değiştiği salınımlı bir ventilasyon paterni ile karakterize farklı bir bozukluktur (4).

¹ Uzm. Dr. Kozluk Devlet Hastanesi Göğüs Hastalıkları Kliniği drtekin2112@gmail.com

8-PREMATÜRLERİN PRİMER SUAS

Preterm infantlarda çok sık görülür. Yaşamın 2-7. günleri arasında apneler oluşur. Solunum merkezinin immaturitesi ile doğrudan ilişkilidir. Ventilatör desteği ve farmakolojik tedavi gerekebilir. Altta yatan komorbiditelerin varlığı, daha ciddi ve uzamış apnelere neden olur. Çalışmalarda <2500 gr infantların %25'i, <1000 gr olanların %84'ünde yenidoğan döneminde apne olduğu bildirilmiştir. Bebeklerin büyük kısmında 43. Haftayla beraber apneler kaybolur.

Çoğu premature yenidoğanda apneler, PSG'den ziyade neonatal yoğun bakım ünitesinde kardiyorespiratuar monitor aracılığıyla teşhis edilir. PSG yapıldığında apnelerin çoğunluğunun (%50-75) mikst apne olduğu, obstrüktif ve santral apnelerin %10-20 oranında görüldüğü tespit edilmiştir. Periyodik solunum paterni de görülebilir (27).

Tanı kriterleri: A+B+C+D

A. Doğum sonrası apne veya siyanoz epizotu veya uykuyla ilişkili santral apne, saturasyon düşüklüğü veya bradikardi gözlenmeli

B. Bebek preterm olmalı

C. PSG veya bir hastane veya evde aşağıdakilerden en az biri gözlenmeli

1-Tekrarlayan uzamış santral apneler

2-Toplam uykunun %5'inde periyodik solunum

D. Tablonun başka bir nedenle açıklanmaması gerekmektedir(24)

KAYNAKLAR

1. Guilleminault C, van den Hoed J, Mitler M: Clinical overview of the sleep apnea syndromes. In: Guilleminault C, Dement WC, ed Sleep Apnea Syndromes. New York, Alan R Liss, 1978: 1-11
2. Lanfranchi PA, Braghiroli A, Bosimini E: Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation.1999 mar 23;99(11):1435-40.doi:10.1161/01.cir99.11.143
3. Amerikan Uyku Tıbbi Akademisi Uluslararası Uyku Bozuklukları Sınıflandırması . Amerikan Uyku Tıbbi Akademisi, 3. baskı.Darien, IL, ABD:2014.
4. Bradley TD, Floras JS Sleep apnea and heart failure: Part II: central sleep apnea.Circulation. 2003 8 April; 107(13):1822-6. doi: 10.1161/01.CIR.0000061758.05044.64.
5. New Classification of Sleep Disorders (ICSD-3) What Has Changed in Sleep Breathing Disorders? Güncel Göğüs Hastalıkları Serisi 2014; 2 (2): 139-151.
6. Naughton MT, Kee K: Sleep apnoea in heart failure: To treat or not to treat?. Solunum bilim. 2017 february; 22(2):217-229. doi: 10.1111/resp.12964
7. Lanfranchi PA, Braghiroli A, Bosimini E: Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation.1999 mar 23;99(11):1435-40.

8. 44. Javaheri S, Parker TJ, Wexler L, Liming JD: Effect of theophylline on sleep-disordered breathing in heart failure. *Solunum bilim.* 2017 february; 22(2):217-229. doi: 10.1111/resp.12964
9. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. *Am J Respir Crit Care Med.* 2006 Jan 15;173(2):234-7. doi: 10.1164/rccm.200507-1035OC.
10. Fontana M, Emdin M, Giannoni A, Iudice: Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. *Am J Cardiol.* 2011 1;107(11):1675-80.doi:10.1016/j.amjcard.2011.01.060
11. Bordier P. Sleep apnoea in patients with heart failure: part II: therapy.*Arch cardiovasc dis.*2009 oct;102(10)711-20. Doi:10i1016/j.acvd.2009.06.005.
12. Beyaz Sol, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. *J Physiol.* 2013 Mar 1;591(5):1179-93.doi:10.1113/jphysiol.2012.245159
13. Billings ME, Johnson DA, Simonelli G: Neighborhood Walking Environment and Activity Level Are Associated With OSA: The Multi-Ethnic Study of Atherosclerosis. *Chest.* 2016 Nov;150(5):1042-1049. doi:10.16/j.chest.2016.06.012
14. Bradley TD, Logan AG, Kimoff RJ: CANPAP Investigators. Continuous positive airway pressure central apnea and heart failure.*N engl J Med:* 2005;353;2025-2033. Doi:10.1056/NEJ-Moa05100
15. Arzt M, Floras JS, Logan AG: CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). 2007 Jun 26;115(25):3173-80.
16. Teschler H, Döhring J, Wang YM: Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. *J Respir Crit Care Med.* 2001; 164 :614-619. Doi:10.1164/ajrccm.164.4.9908114.
17. S, Brown LK, Randerath WJ. Positive airway pressure therapy with adaptive servoventilation: part 1: operational algorithms.*Chest.* 2014; 146 :514–523. doi: 10.1378/chest.13-1776.
18. Arzt M, Wensel R, Montalvan S: Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure.*Chest.* 2008; 134 :61-66. doi: 10.1378/chest.07-1620.
19. D'Elia E, Vanoli E, La Rovere MT: Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients: beneficial effects on autonomic modulation of heart rate.*J Cardiovasc Med (Hagerstown)* 2013; 14 :296–300. doi: **10.2459/JCM.0b013e32835364b2**
20. Oldenburg O, Schmidt A, Lamp B: Horstkotte Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration *Eur J Heart Fail* 2008 Jun;10(6):581-6. doi:10.1016/j.ejheart.2008.04.007
21. Hastings PC, Vazir A, Meadows GE: Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study. *Int J Cardiol.* 2010; 139 :17–24. doi: 10.1016/j.ijcard.2008.08.022.
22. Cowie MR, Woehrle H, Wegscheider K: Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *N Engl J Med.* 2015; 373 :1095–1105.
23. Javaheri S, Brown LK, Randerath W: SERVE-HF: CSERVE-HF: More Questions Than Answers. *Chest.* 2016; 149 :900–904. doi: 10.1016/j.chest.2015.12.021.
24. Bradley TD, Floras JS: ADVENT-HF The SERVE-HF Trial. *Can Respir J.* 2015; 22 :313. doi: 10.1155/2015/751615
25. Costanzo MR, Ponikowski P, Javaheri S, remedé System Pivotal Trial Study Group. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. *Lancet.* 2016; 388 :974-982. doi: 10.1016/S0140-6736(16)30961

26. Uyküder 2021 Uykü Bozuklukları Kongresi 12. Uykü Bozuklukları Kursu 30 Nisan /1-2 Mayıs 2021 - Dijital Platform
27. Barcroft J.Kanın solunum fonksiyonu, bölüm 2. Yüksek irtifadan dersler . Cambridge : Cambridge University Press , 1925 .
28. Some experiences of mountain sickness in the ANDES . Journal of Tropical Medicine and Hygiene, 1913 ; 16 : 313 – 320.
29. Anholm JD ,Powles AC ,Downey R ,Houston CS :Everest Operasyonu. Operation Everest II: arterial oxygen saturation and sleep at extreme simulated altitude. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):817-26.doi: 10.1164/ajrccm/145.4_Pt_1.817.
30. F Goldenberg , JP Richalet , I Onnen . Sleep apneas and high altitude newcomersUykü apneas. Int J Spor Med 1992 ; 13 : S34 - S36
31. . Fischer R, Lang S, Leitzl M:Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 2004;23:47-52. doi: 10.1183/09031936.03.00113102.
32. 4. Nickol A, Leverment J, Richards P: Cleland J, et al. Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study. J Sleep Res 2006;15:445-54. doi: 10.1111/j.1365-2869.2006.00558.x.
33. Beaumont M, Batejat D, Coste O: Clère JM, et al. Effects of Zolpidem and Zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4000 m. Neuropsychobiology 2004;49:154-62. doi: 10.1159/000076723.
34. Aurora RN, Chowdhuri S, Ramar K: Lamm CI, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidencebased literature review and meta-analyses. Sleep 2012;35:17-40. doi: 10.5665/sleep.1580
35. Han B, Compton WM, Blanco C: Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med:2017;167:293-301. doi:10.7326/M17-0865.
36. Seth P, Scholl L, Rudd RA:Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States,2015-2016MMWR Morb Mortal Wkly Rep. Doi:10.15585/mmwr.mm6712a1.
37. Bailey PL, Lu JK, Pace NL, et al. Effects of intrathecal morphine on the ventilatory response to hypoxia. N Engl J Med. 2000;343:1228–1234. doi: 10.1056/NEJM200010263431705
38. Amerikan Uykü Tıbbi Akademisi. Uluslararası Uykü Bozuklukları Sınıflandırması, Üçüncü Baskı: Teşhis ve Kodlama Kılavuzu. 2014.Amerikan Uykü Tıbbi Akademisi;
39. Javaheri S, Dempsey JA. Central sleep apnea.Comp. Physiol.2013;3; 141-163i doi:10.1002/chpt.c.110057
40. Correa D, Farney RJ, Chung F: Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015 Jun;120(6):1273-85.doi: 10.1213/ANE.0000000000000672
41. Lalley PM. Opiate slowing of feline respiratory rhythm and effects on putative medullary phase-regulating neurons. J Physiol Regul Integr Comp Physiol. 2006;290:R1387–R1396. doi:10.1152/ajpregu.00530.2005
42. Aurora RN, Chowdhuri S, Ramar K, et al:The treatment of central sleep apnea syndromes im adults practice parameters with anevidence -based literature review and meta -analyses. Sleep .2012;3517-40
43. Rosen IM, Aurora RN, Kirsch DB, ve diğerleri; Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine PositionStatement. J Clin Sleep Med. 2019;15:1671. Doi:10.5664/jcsm.8062
44. Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.J Clin Uykü Med. 2007;3:455–461.
45. Naughton MT. Cheyne-Stokes respiration: friend or foe? Thorax. 2012;67:357–360. doi: 10.1136/thoraxjnl-2011-200927

46. Wang D, Rowsell L, Yee BJ. Positive airway pressure treatment for opioid-related central sleep apnea, where are we now? *Sleep and breathing*. 2014;18:229–231.
47. Farney RJ, Walker JM, Cloward TV: Sleep-disordered breathing associated with long-term opioid therapy. *Chest*. 2003;123:632–639. doi: 10.1378/chest.123.2.632
48. Chowdhuri S, Ghabsha A, Sinha P: Treatment of central sleep apnea in U.S. veterans. *J Clin sleep Med*. 2012;8:555-563. doi: 10.5664/jcsm.2156
49. Smith JC, Abdala AP, Koizumi H: Memeli beyin sapı solunum ağının mekansal ve fonksiyonel mimarisi: üç salınım mekanizmasının hiyerarşisi. Spatial and functional architecture of the mammalian brain stem respiratory network: a hierarchy of three oscillatory mechanisms. *J Nörofizyol*. 2007;98:3370–3387. doi: 10.1152/jn.00985.2007.
50. Schwarzer A, Aichinger-Hinterhofer M, Maier C: Sleep-disordered breathing decreases after opioid withdrawal: results of a prospective controlled trial. *pain*. 2015;156:2167-2174. doi:10.1097/j.pain.0000000000000279.
51. Wang D, Lintzeris N, Leung S: Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. *Eur Respir J*. 2015;46:102–1205. Doi:10.1183/09031936.00051315
52. Javaheri S, Harris N, Howard J: Adaptive servoventilation for treatment of opioid-associated central sleep apnea. *J Clin sleep Med*. 2014;10:637–643. doi: 10.5664/jcsm.3788
53. Javaheri S, Malik A, Smith J: Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids. *J Clin sleep Med*. 2008;4:305–310.
54. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *N Engl J Med*. 2015;373:1095–1105. doi: 10.1056/NEJ-Moa1506459
55. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. *J Am Coll Cardiol*. 2017;69:841-858. doi:10.1016/j.jacc.2016.11.069.
56. DeBacker WA, Verbraecken J, Willemen M: Central apnea index decreases after prolonged treatment with acetazolamide. *J Respir Crit Care Med*. 1995 Ocak; 151(1):87-91. doi: 10.1164/ajrccm.151.1.7812578.
57. Roehrs T, Conway W, Wittig R: Sleep-wake complaints in patients with sleep-related respiratory disturbances. *Rev Respir Dis*. 1985 september; 132(3):520-3. doi:10.1164/arrd.1985.132.3.520
58. Aurora RN, Chowdhuri S, Ramar K: The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep* 2012; 35: 17-40.
59. Bradley TD, McNicholas WT, Rutherford R: Clinical and physiologic heterogeneity of the central sleep apnea syndrome. *Rev Respir Dis*. 1986 Agu; 134(2):217-21. doi: 10.1164/arrd.1986.134.2.217.
60. Bonnet M, Dexter J, Arand D. The effect of triazolam on arousal and respiration in central sleep apnea patients. *Sleep* 1990; 13: 31-41.
61. Shahrokh Javaheri, MD Scott McKane, MS. Transvenous phrenic nerve stimulation to treat idiopathic central sleep apnea: *Journal of Clinical Sleep Medicine* Vol. 16, No. 12; :December 15, 2020
62. Nigam G, Pathak C, Riaz M Ann. A systematic review on prevalence and risk factors associated with treatment-emergent central sleep apnea. *Ann Thorac Med*. 2016 Jul-Sep; 11(3): 202–210. doi:10.4103/1817-1737.185761.
63. Westhoff M, Arzt M, Litterst P. Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure. *Seep and breathing* 16, 71-78(2012)
64. Khan MT, Franco RA Complex sleep apnea syndrome *Sleep dis*. 2014; 2014:798487. Doi:10.1155/2014/798487